Spray, Then Stay

Spravato means supervised visits, monitoring and a ride home. Know what you want to be able to do again and what the studies can and can’t promise before you commit.

If previous antidepressants haven’t done enough for your depression, Spravato is worth discussing. It helps some adults, but the visits take planning and you need a way to tell whether it’s helping you. Getting back to your life is the reason to do this, rather than adding another prescription to the collection.

What it’s actually approved for

Spravato is esketamine nasal spray. In the US, adults with treatment resistant depression can get it alone or with an oral antidepressant. The separate approval for depressive symptoms with acute suicidal thoughts or behavior requires an oral antidepressant. It hasn’t been shown to prevent suicide, and feeling better doesn’t remove a need for hospital care. Keep those limits in the conversation. [1]

Ask which situation the clinician is considering and what previous treatment records they need. Then keep the rules straight. What a clinic requires, what insurance will pay for and what the drug is approved for are separate questions. An answer to one doesn’t settle the others.

The visit includes the wait

You administer the spray under direct supervision in a certified healthcare setting. Outpatients enroll in the safety program called REMS. Staff monitor sedation, dissociation and breathing, including oxygen monitoring. You don’t take the bottle home. [2]

Dissociation can feel like detachment from yourself or your surroundings. Promising you won’t feel altered would be bullshit. Observation lasts at least two hours. After that, the clinician still decides when you’re ready to leave, so don’t plan around an automatic release at the two hour mark. [2]

Get a ride home. Don’t drive or operate machinery until the next day after restful sleep, even if you feel fine earlier. [1] Ask how much time to allow beyond monitoring, who can collect you and whom to contact if you react after leaving. Don’t plan your workday around driving yourself back from the appointment.

The first month isn’t a lifetime schedule

For treatment resistant depression, the labeled schedule starts twice weekly for four weeks, then weekly for four weeks. Later visits can be weekly or every two weeks, adjusted to maintain improvement. Review the benefit after the initial phase. A starting schedule isn’t a commitment to keep doing visits forever. [1]

Agree on what’d make continuing worthwhile and how you’ll track side effects. Name something you want back, like finishing work or enjoying friends. A symptom score is useful, but the clinician also needs to hear whether Tuesday looks any different.

What the studies found

A 2025 placebo controlled monotherapy trial analyzed 378 adults in its main efficacy group over four weeks. Average depression scores improved more with esketamine, with group differences of 5.1 to 6.8 points on the MADRS scale at day 28. So esketamine helped in that study without an oral antidepressant. It still doesn’t tell us whether it’ll help you. [3]

Another trial compared esketamine with extended release quetiapine, both added to an oral antidepressant. Among 676 participants, remission at eight weeks was 27.1 percent versus 17.6 percent. Participants knew what they got; symptom raters didn’t. That doesn’t place esketamine above every other depression treatment, and it doesn’t establish superiority over IV ketamine. Different claim, different study needed. [4]

In a maintenance trial, people were randomized after already improving on esketamine plus an oral antidepressant. Relapse happened in 26.7 percent of stable remitters who kept esketamine and 45.3 percent who switched to placebo spray. Both groups kept the oral medication. That’s support for continuing in some people who benefit, not a personal forecast or a lifetime visit schedule for everybody. [5]

The manufacturer was involved in these studies. Janssen funded the comparison trial, and the other two list company employees among their authors. That doesn’t erase a positive result. It also doesn’t answer the things these studies didn’t test, so keep the company involvement in the conversation when you discuss the findings. [3] [4] [5]

Get the practical stuff settled before starting

Bring blood pressure, vascular or brain bleeding history, substance use, psychosis, pregnancy possibility and your entire medicine list into the assessment. Some conditions rule treatment out; others need an individual decision. Alcohol, sedating medicines and certain other drugs can add risk. Don’t change them yourself to get through the intake requirements. [1]

Get written costs for the medication and supervised visit, and confirm what your own coverage pays. Include transport and time off work in the plan. There’s no honest universal cash price or coverage promise to give you here.

If you can’t stay safe, get emergency help now. Don’t wait for a Spravato appointment. Its limits around suicide prevention don’t disappear when symptoms improve. [1]

Sources

1. Spravato prescribing information, DailyMed. Selected indications, scheduling, precautions, interactions and driving instructions. Returned PI highlights revised March 2026; medication guide September 2026, document version 21 effective September 22, 2026.
2. Spravato REMS Program Overview. Selected supervision, monitoring and patient requirements, June 2025 document.
3. Janik et al., 2025, esketamine monotherapy for treatment resistant depression. Complete PubMed abstract and returned disclosures; not the full paper.
4. Reif et al., 2023, esketamine versus quetiapine. Complete PubMed abstract including funding; not the full paper.
5. Daly et al., 2019, esketamine relapse prevention. Complete PubMed abstract and selected disclosures; not the full paper.